|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This is the first report showing a preferential expression of Lis1 gene in CD133+ glioblastoma cells.
|
28607604 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that miR‑141 is suppressed in sorted cluster of differentiation (CD) 133(+) glioblastoma stem cells (GSCs) compared with CD133(‑) non‑glioblastoma stem cells (NSCs) from patient samples.
|
28535010 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Double-immunofluorescence stainings in glioblastomas revealed co-expression of JAM-A with CD133, SOX2, nestin, and GFAP in tumor cells as well as some co-expression with the microglial/macrophage marker IBA-1.
|
28677106 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD133, a putative stem cell marker in normal tissue and malignant brain tumors, enhances multidrug resistant gene 1 (MDR1) expression following chemotherapy in adult malignant glioblastomas.
|
28137267 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
METHODS The inhibitory effects of SFN on established cell lines, early primary cultures, CD133-positive GSCs, GSC-derived spheroids, and GBM xenografts were evaluated using various methods, including GSC isolation and the sphere-forming assay, analysis of reactive oxygen species (ROS) and apoptosis, cell growth inhibition assay, comet assays for assessing SFN-triggered DNA damage, confocal microscopy, Western blot analysis, and the determination of in vivo efficacy as assessed in human GBM xenograft models.
|
28059653 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.
|
28241049 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GSCs from human U87 and rat C6 glioblastoma cell lines were isolated via magnetic cell sorting using CD133 as a cancer stem cell marker.
|
29284440 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that CD133+ U87 glioblastoma cells derived exosome-mediated miRNA transduction play an important role of mediating a proangiogenic response and glioma cells proliferation, and that the exosomal pathway constitutes a potentially targetable driver of hypoxia-dependent intercellular signaling during tumor development.
|
28948499 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 Regulates IL-1β Signaling and Neutrophil Recruitment in Glioblastoma.
|
28736425 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present review article is focused on two important markers in current research viz.Prominin-1 and NPM1 in glioblastoma.
|
28770964 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD9 silencing in three CD133+ glioblastoma cell lines (NCH644, NCH421k and NCH660h) led to decreased cell proliferation, survival, invasion, and self-renewal ability, and altered expression of the stem-cell markers CD133, nestin and SOX2.
|
26573230 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the current study, miR-203 expression was reduced in CD133(+) GBM-SCs derived from six human GBM biopsies.
|
27484906 |
2016 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant methylation of CD133 was observed in glioblastoma.
|
26757925 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report that our in vitro model enriched for a CD15+/CD133- BTSC population, mirroring the phenotype of BTSCs in recurrent GBM.
|
26498281 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
|
27530866 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Following prolonged chemotherapy, MDR protein 1 (MDR1) and CD133 increase in recurrent glioblastomas.
|
25823028 |
2016 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, H19 was also significantly overexpressed in CD133(+) glioblastoma cells, and overexpression of H19 was associated with increased neurosphere formation of glioblastoma cells.
|
26274999 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we isolated CD133-positive (CD133+) and CD133-negative (CD133-) cells from glioblastoma U98G and U87MG cell lines.
|
27343059 |
2016 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, HMGA2 expression was increased in CD133+ GBM neurosphere cells compared to CD133- cells.
|
27102002 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, CD133-positive U251 GBM cells were used as a putative GBM-SC population to identify the functions of Netrin-1.
|
27651158 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evidences have suggested that CD133 is a marker for a subset of glioblastoma cancer stem cells.
|
27338789 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we demonstrated that two functionally related microRNAs, miR-20a and -106a (miR-20a/106a), were capable of enhancing the invasiveness of CD133(+) glioma stem cells (GSCs) isolated from both glioblastoma cell line U87 and primary human glioma specimens.
|
24704830 |
2015 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
|
25749043 |
2015 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using gain/loss-of-function studies for CD133 we assessed the in vitro self-renewal and in vivo tumor formation capabilities of patient-derived glioblastoma cells.
|
26152745 |
2015 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133(+) GSCs, a kind of GSCs line, was established from human glioblastoma tissues.
|
26150336 |
2015 |